Novel marker genes and small molecule drugs for radiotherapy resistance in cervical cancer identified based on

Yang Liu1, Xin Pan1, Xu Zhang1

  • 1Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.

Discover Oncology
|May 19, 2025
PubMed

Insights

This study reveals key molecular and cellular drivers of cervical cancer radioresistance using multi-omics and machine learning. Findings identify novel biomarkers and a prognostic model to predict treatment response and guide personalized therapies.

Area of Science:

  • Oncology
  • Genomics
  • Bioinformatics

Background:

  • Radiotherapy is a primary cervical cancer treatment, but patient response varies significantly.
  • Understanding molecular radioresistance mechanisms is crucial for improving treatment efficacy.

Purpose of the Study:

  • To investigate molecular and cellular mechanisms of radioresistance in cervical cancer.
  • To develop a machine learning-based prognostic model for radiotherapy response.

Main Methods:

  • Utilized multi-omics data (transcriptome, methylation, single-cell sequencing) from TCGA and GEO databases.
  • Performed differential gene/methylation analysis, single-cell processing (Seurat, CellTypist), and machine learning (Cox regression).
  • Conducted immune infiltration and drug sensitivity analyses.

Main Results:

  • Identified 845 upregulated and 460 downregulated genes, and 3042 downregulated/158 upregulated methylation loci related to radioresistance.
  • Single-cell analysis revealed 13 cell types, with aneuploid cells in epithelial cells and immune cells (monocytes, ILCs, T cells) linked to resistance.
  • Developed and validated a robust prognostic model predicting radiotherapy efficacy and immune infiltration.

Conclusions:

  • The study provides a comprehensive framework for identifying radioresistance markers in cervical cancer.
  • The developed prognostic model and identified drug candidates offer potential for personalized treatment strategies.
  • Insights into molecular and cellular mechanisms can guide future therapeutic interventions for radioresistant cervical cancer.